The Lung Inflammatory Disease Program of Excellence in Glycosciences (LID-PEG) has Projects and Cores at three institutions and a breadth of capabilities ranging from chemistry to preclinical therapeutic models. With this diversity, communications will be a key to LID-PEG progress and success. A major role in effective communication will be provided by Core A, the Administrative Core. Core A will take responsibility for inter-program communications both through web-based video conferencing and face-to-face meetings. The Core will coordinate and oversee the regular video-conference meetings of the Executive Committee, organize the annual Program Group Meeting (which will rotate among the three sites), organize meetings of the LID-PEG with its Internal and External advisory boards and support LID-PEG participation in the annual Investigator's meeting in Bethesda. In addition to travel planning and reimbursement for LID-PEG meeting participants. Core A will coordinate communications with NHLBI and the Administrative Center, manage budgets and fulfill NIH reporting requirements.

Public Health Relevance

This Program brings together scientists from across the country to combine diverse expertise in glycosciences with the goal of discovering new therapies for asthma, COPD and other lung and cardiovascular inflammatory diseases. Effective communication is essential to this goal, and Core A will take the lead in ensuring efficient communications among LID-PEG members.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL107151-03
Application #
8477259
Study Section
Special Emphasis Panel (ZHL1-CSR-H)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
3
Fiscal Year
2013
Total Cost
$145,858
Indirect Cost
$57,398
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Stowell, Sean R; Arthur, Connie M; McBride, Ryan et al. (2014) Microbial glycan microarrays define key features of host-microbial interactions. Nat Chem Biol 10:470-6
Kawasaki, Norihito; Rillahan, Cory D; Cheng, Tan-Yun et al. (2014) Targeted delivery of mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activation. J Immunol 193:1560-6
Kiwamoto, Takumi; Brummet, Mary E; Wu, Fan et al. (2014) Mice deficient in the St3gal3 gene product *2,3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation. J Allergy Clin Immunol 133:240-7.e1-3
Macauley, Matthew S; Crocker, Paul R; Paulson, James C (2014) Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 14:653-66
Cho, Seok Hyun; Oh, Sun Young; Lane, Andrew P et al. (2014) Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways. PLoS One 9:e103685
Fang, Ping; Zhou, Li; Zhou, Yuqi et al. (2014) Immune modulatory effects of IL-22 on allergen-induced pulmonary inflammation. PLoS One 9:e107454
Nix, David B; Kumagai, Tadahiro; Katoh, Toshihiko et al. (2014) Improved in-gel reductive ?-elimination for comprehensive O-linked and sulfo-glycomics by mass spectrometry. J Vis Exp :e51840
Rillahan, Cory D; Macauley, Matthew S; Schwartz, Erik et al. (2014) Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas. Chem Sci 5:2398-2406
Kiwamoto, Takumi; Katoh, Toshihiko; Tiemeyer, Michael et al. (2013) The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation. Curr Opin Allergy Clin Immunol 13:106-11
Rillahan, Cory D; Schwartz, Erik; Rademacher, Christoph et al. (2013) On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7. ACS Chem Biol 8:1417-22

Showing the most recent 10 out of 15 publications